drugset / Trial / NCT00397228
ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
Phase 2
Completed
27 enrolled
Molecular NeuroImaging
Institute for Neurodegenerative Disorders · collab
NaSingle-groupOpen-labelDiagnostic
Summary
After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging within 2-6 weeks of the injection 1.
Timeline
- Start
- 2006-11
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALTROPANE® | Diagnostic / imaging agent | — | — |